Clinical Trial

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

Name: PD-1 Inhibitors Maintenance for cHL Post-autoHCT — clinical trial record (NCT06812858)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL)

Protocol Amendment History 1 change

notable Primary completion moved earlier: 2029-09 -> 2029-05 2026-05-23

Trial Details

NCT Number	NCT06812858
Lead Sponsor	St. Petersburg State Pavlov Medical University
Conditions	Hodgkin Lymphoma
Enrollment	83 participants
Start Date	2024-01-09
Primary Completion	2029-05 (estimated)
Study Completion	2030-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-22